Single ascending dose, safety, tolerability and pharmacokinetic study of Sa001 in healthy subjects

Trial Profile

Single ascending dose, safety, tolerability and pharmacokinetic study of Sa001 in healthy subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Mar 2018

At a glance

  • Drugs SA 001 (Primary) ; Rebamipide
  • Indications Dry eyes
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 28 Mar 2018 New trial record
    • 24 Mar 2018 Results assessing safety, tolerability and pharmacokinetic of Sa001, presented at the 119th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top